SEARCH

SEARCH BY CITATION

References

  • Alon T., Hemo I., Itin A., Pe’er J., Stone J. and Keshet E. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1, 10241028.
  • Ankoma-Sey V., Wang Y. and Dai Z. (2000) Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 31, 141148.
  • Beckmann N., Schuler A., Mueggler T., Meyer E. P., Wiederhold K. H., Staufenbiel M. and Krucker T. (2003) Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer’s disease. J. Neurosci. 23, 84538459.
  • Cao Y., Linden P., Farnebo J., Cao R., Eriksson A., Kumar V., Qi J. H., Claesson-Welsh L. and Alitalo K. (1998) Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl Acad. Sci. USA 95, 1438914394.
  • Carmeliet P., Ferreira V., Breier G. et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435439.
  • Cerpa W., Dinamarca M. C. and Inestrosa N. C. (2008) Structure-function implications in Alzheimer’s disease: effect of Abeta oligomers at central synapses. Curr. Alzheimer Res. 5, 233243.
  • Connolly D. T., Heuvelman D. M., Nelson R., Olander J. V., Eppley B. L., Delfino J. J., Siegel N. R., Leimgruber R. M. and Feder J. (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84, 14701478.
  • Donnini S., Cantara S., Morbidelli L., Giachetti A. and Ziche M. (2006) FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium. Cell Death Differ. 13, 10881096.
  • Farkas E. and Luiten P. G. (2001) Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog. Neurobiol. 64, 575611.
  • Ferrara N. (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 1014.
  • Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O’Shea K. S., Powell-Braxton L., Hillan K. J. and Moore M. W. (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439442.
  • Fischer S., Sharma H. S., Karliczek G. F. and Schaper W. (1995) Expression of vascular permeability factor/vascular endothelial growth factor in pig cerebral microvascular endothelial cells and its upregulation by adenosine. Brain Res. Mol. Brain Res. 28, 141148.
  • Gaillard P. J. and De Boer A. G. (2000) Relationship between permeability status of the blood–brain barrier and in vitro permeability coefficient of a drug. Eur. J. Pharm. Sci. 12, 95102.
  • Gebbink M. F., Voest E. E. and Reijerkerk A. (2004) Do antiangiogenic protein fragments have amyloid properties? Blood 104, 16011605.
  • Gerber H. P., McMurtrey A., Kowalski J., Yan M., Keyt B. A., Dixit V. and Ferrara N. (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 3033630343.
  • Gorevic P. D., Goni F., Pons-Estel B., Alvarez F., Peress N. S. and Frangione B. (1986) Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer’s disease: immunohistological studies. J. Neuropathol. Exp. Neurol. 45, 647664.
  • Harmeier A., Wozny C., Rost B. R. et al. (2009) Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. J. Neurosci. 29, 75827590.
  • Jain R. K. (2002) Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin. Oncol. 29, 39.
  • Jarvis K., Assis-Nascimento P., Mudd L. M. and Montague J. R. (2007) Beta-amyloid toxicity and reversal in embryonic rat septal neurons. Neurosci. Lett. 423, 184188.
  • Jellinger K. A. and Attems J. (2005) Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J. Neurol. Sci. 229–230, 3741.
  • Johnson N. A., Jahng G. H., Weiner M. W., Miller B. L., Chui H. C., Jagust W. J., Gorno-Tempini M. L. and Schuff N. (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234, 851859.
  • Kalaria R. N., Cohen D. L., Premkumar D. R., Nag S., LaManna J. C. and Lust W. D. (1998) Vascular endothelial growth factor in Alzheimer’s disease and experimental cerebral ischemia. Brain Res. Mol. Brain Res. 62, 101105.
  • Kim E. H., Na H. K. and Surh Y. J. (2006) Upregulation of VEGF by 15-deoxy-Delta12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells. Ann. N Y Acad. Sci. 1090, 375384.
  • Krum J. M. and Khaibullina A. (2003) Inhibition of endogenous VEGF impedes revascularization and astroglial proliferation: roles for VEGF in brain repair. Exp. Neurol. 181, 241257.
  • Krum J. M., Mani N. and Rosenstein J. M. (2008) Roles of the endogenous VEGF receptors flt-1 and flk-1 in astroglial and vascular remodeling after brain injury. Exp. Neurol. 212, 108117.
  • Larkin M. A., Blackshields G., Brown N. P. et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23, 29472948.
  • Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V. and Ferrara N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 13061309.
  • Liu Y., Cox S. R., Morita T. and Kourembanas S. (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res. 77, 638643.
  • Magrane J., Christensen R. A., Rosen K. M., Veereshwarayya V. and Querfurth H. W. (2006) Dissociation of ERK and Akt signaling in endothelial cell angiogenic responses to beta-amyloid. Exp. Cell Res. 312, 9961010.
  • Mathura V. S., Paris D., Ait-Ghezala G., Quadros A., Patel N. S., Kolippakkam D. N., Volmar C. H. and Mullan M. J. (2005) Model of Alzheimer’s disease amyloid-beta peptide based on a RNA binding protein. Biochem. Biophys. Res. Commun. 332, 585592.
  • Meyer E. P., Ulmann-Schuler A., Staufenbiel M. and Krucker T. (2008) Altered morphology and 3D architecture of brain vasculature in a mouse model for Alzheimer’s disease. Proc. Natl Acad. Sci. USA 105, 35873592.
  • Morris G. M., Goodsell D. S., Halliday R. S., Huey R., Hart W. E., Belew R. K. and Olson A. J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19, 16391662.
  • Neufeld G., Cohen T., Gengrinovitch S. and Poltorak Z. (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13, 922.
  • Pardridge W. M., Vinters H. V., Yang J., Eisenberg J., Choi T. B., Tourtellotte W. W., Huebner V. and Shively J. E. (1987) Amyloid angiopathy of Alzheimer’s disease: amino acid composition and partial sequence of a 4,200-dalton peptide isolated from cortical microvessels. J. Neurochem. 49, 13941401.
  • Paris D., Patel N., DelleDonne A., Quadros A., Smeed R. and Mullan M. (2004a) Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci. Lett. 366, 8085.
  • Paris D., Quadros A., Humphrey J., Patel N., Crescentini R., Crawford F. and Mullan M. (2004b) Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res. 999, 5361.
  • Paris D., Townsend K., Quadros A. et al. (2004c) Inhibition of angiogenesis by Abeta peptides. Angiogenesis 7, 7585.
  • Paris D., Ait-Ghezala G., Mathura V. S., Patel N., Quadros A., Laporte V. and Mullan M. (2005) Anti-angiogenic activity of the mutant Dutch A(beta) peptide on human brain microvascular endothelial cells. Brain Res. Mol. Brain Res. 136, 212230.
  • Patel N. S., Quadros A., Brem S., Wotoczek-Obadia M., Mathura V. S., Laporte V., Mullan M. and Paris D. (2008) Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide. Amyloid 15, 519.
  • Presta M., Dell’Era P., Mitola S., Moroni E., Ronca R. and Rusnati M. (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16, 159178.
  • Rosenstein J. M., Mani N., Khaibullina A. and Krum J. M. (2003) Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J. Neurosci. 23, 1103611044.
  • Selkoe D. J. (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106113.
  • Selkoe D. J., Abraham C. R., Podlisny M. B. and Duffy L. K. (1986) Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer’s disease. J. Neurochem. 46, 18201834.
  • Senger D. R., Galli S. J., Dvorak A. M., Perruzzi C. A., Harvey V. S. and Dvorak H. F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983985.
  • Shinkaruk S., Bayle M., Lain G. and Deleris G. (2003) Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr. Med. Chem. Anticancer Agents 3, 95117.
  • Shore P. M., Jackson E. K., Wisniewski S. R., Clark R. S., Adelson P. D. and Kochanek P. M. (2004) Vascular endothelial growth factor is increased in cerebrospinal fluid after traumatic brain injury in infants and children. Neurosurgery 54, 605611; discussion 611–602.
  • Slevin M., Krupinski J., Slowik A., Rubio F., Szczudlik A. and Gaffney J. (2000) Activation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and VEGF in the human brain following acute ischaemic stroke. Neuroreport 11, 27592764.
  • Tarkowski E., Issa R., Sjogren M., Wallin A., Blennow K., Tarkowski A. and Kumar P. (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer’s disease and vascular dementia. Neurobiol. Aging 23, 237243.
  • Thirumangalakudi L., Samany P. G., Owoso A., Wiskar B. and Grammas P. (2006) Angiogenic proteins are expressed by brain blood vessels in Alzheimer’s disease. J. Alzheimers Dis. 10, 111118.
  • Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M. and Heldin C. H. (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 2698826995.
  • Weller R. O., Yow H. Y., Preston S. D., Mazanti I. and Nicoll J. A. (2002) Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer’s disease. Ann. N Y Acad. Sci. 977, 162168.
  • Weller R. O., Cohen N. R. and Nicoll J. A. (2004) Cerebrovascular disease and the pathophysiology of Alzheimer’s disease. Implications for therapy. Panminerva Med. 46, 239251.
  • Wu Z., Guo H., Chow N. et al. (2005) Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 11, 959965.
  • Zhu Z. and Witte L. (1999) Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest. New Drugs 17, 195212.